Cargando…
Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient’s Subjective Quality of Life, Well-Being, and Satisfaction
Schizophrenia (SZ) is among the twenty most disabling diseases worldwide. Subjective quality of life, well-being, and satisfaction are core elements to achieving personal recovery from the disorder. Long-acting injectable second-generation antipsychotics (SGA-LAIs) represent a valid therapeutic opti...
Autores principales: | Brasso, Claudio, Bellino, Silvio, Bozzatello, Paola, Montemagni, Cristiana, Nobili, Marco Giuseppe Alberto, Sgro, Rodolfo, Rocca, Paola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672596/ https://www.ncbi.nlm.nih.gov/pubmed/38002600 http://dx.doi.org/10.3390/jcm12226985 |
Ejemplares similares
-
Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
por: Brasso, Claudio, et al.
Publicado: (2017) -
Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review
por: Brasso, Claudio, et al.
Publicado: (2023) -
The relative contributions of insight and neurocognition to intrinsic motivation in schizophrenia
por: Brasso, Claudio, et al.
Publicado: (2022) -
Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni, Cristiana, et al.
Publicado: (2016) -
Primary Psychosis: Risk and Protective Factors and Early Detection of the Onset
por: Brasso, Claudio, et al.
Publicado: (2021)